These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38695855)

  • 1. Alternative Splicing of RNA Is Excessive in Multiple Sclerosis and Not Linked to Gene Expression Levels: Dysregulation Is Corrected by IFN-β.
    Reder AT; Goel A; Garcia T; Feng X
    J Interferon Cytokine Res; 2024 Aug; 44(8):355-371. PubMed ID: 38695855
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection.
    Feng X; Bao R; Li L; Deisenhammer F; Arnason BGW; Reder AT
    EBioMedicine; 2019 Nov; 49():269-283. PubMed ID: 31648992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1.
    Feng X; Petraglia AL; Chen M; Byskosh PV; Boos MD; Reder AT
    J Neuroimmunol; 2002 Aug; 129(1-2):205-15. PubMed ID: 12161037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of membrane bound and soluble ICAM 1 in human endothelium and blood mononuclear cells: effects of interferon beta-1a.
    Giorelli M; De Blasi A; Defazio G; Avolio C; Iacovelli L; Livrea P; Trojano M
    Cell Commun Adhes; 2002; 9(5-6):259-72. PubMed ID: 12745437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative Splicing in Multiple Sclerosis: A Promising Biomarker of Therapeutic Response to Interferon-β.
    Dhib-Jalbut S
    J Interferon Cytokine Res; 2024 Aug; 44(8):335-336. PubMed ID: 38800963
    [No Abstract]   [Full Text] [Related]  

  • 6. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis.
    Hoffmann S; Cepok S; Grummel V; Lehmann-Horn K; Hackermüller J; Stadler PF; Hartung HP; Berthele A; Deisenhammer F; Wassmuth R; Hemmer B
    Am J Hum Genet; 2008 Aug; 83(2):219-27. PubMed ID: 18656179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-β: a longitudinal study in multiple sclerosis patients.
    Sánchez López AJ; Román-Vega L; Ramil Tojeiro E; Giuffrida A; García-Merino A
    Clin Exp Immunol; 2015 Jan; 179(1):119-27. PubMed ID: 25169051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-Analysis of Multiple Sclerosis Microarray Data Reveals Dysregulation in RNA Splicing Regulatory Genes.
    Paraboschi EM; Cardamone G; Rimoldi V; Gemmati D; Spreafico M; Duga S; Soldà G; Asselta R
    Int J Mol Sci; 2015 Sep; 16(10):23463-81. PubMed ID: 26437396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance.
    Hundeshagen A; Hecker M; Paap BK; Angerstein C; Kandulski O; Fatum C; Hartmann C; Koczan D; Thiesen HJ; Zettl UK
    J Neuroinflammation; 2012 Jun; 9():140. PubMed ID: 22727118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta.
    Ozenci V; Kouwenhoven M; Teleshova N; Pashenkov M; Fredrikson S; Link H
    J Neuroimmunol; 2000 Aug; 108(1-2):236-43. PubMed ID: 10900359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment.
    Aliaga-Gaspar P; Hurtado-Guerrero I; Ciano-Petersen NL; Urbaneja P; Brichette-Mieg I; Reyes V; Rodriguez-Bada JL; Alvarez-Lafuente R; Arroyo R; Quintana E; Ramió-Torrentà L; Alonso A; Leyva L; Fernández O; Oliver-Martos B
    Front Immunol; 2021; 12():778204. PubMed ID: 34975865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon Signature's Members, a Novel Altered Correlation upon Interferon-β Treatment in Multiple Sclerosis Patients.
    Jabbari S; Hosseinpourfeizi M; Safaralizadeh R; Baradaran B
    Curr Mol Med; 2024; 24(10):1301-1306. PubMed ID: 37842895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonistic action of IFN-beta and IFN-gamma on high affinity Fc gamma receptor expression in healthy controls and multiple sclerosis patients.
    Van Weyenbergh J; Lipinski P; Abadie A; Chabas D; Blank U; Liblau R; Wietzerbin J
    J Immunol; 1998 Aug; 161(3):1568-74. PubMed ID: 9686625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative splicing in multiple sclerosis and other autoimmune diseases.
    Evsyukova I; Somarelli JA; Gregory SG; Garcia-Blanco MA
    RNA Biol; 2010; 7(4):462-73. PubMed ID: 20639696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis.
    Malhotra S; Río J; Urcelay E; Nurtdinov R; Bustamante MF; Fernández O; Oliver B; Zettl U; Brassat D; Killestein J; Lechner-Scott J; Drulovic J; Chan A; Martinelli-Boneschi F; García-Merino A; Montalban X; Comabella M
    Brain; 2015 Mar; 138(Pt 3):644-52. PubMed ID: 25586466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics of Type I interferon therapy: a survey of response-modifying genes.
    O'Doherty C; Villoslada P; Vandenbroeck K
    Cytokine Growth Factor Rev; 2007; 18(3-4):211-22. PubMed ID: 17540610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomics: mRNA and alternative splicing.
    Sánchez-Pla A; Reverter F; Ruíz de Villa MC; Comabella M
    J Neuroimmunol; 2012 Jul; 248(1-2):23-31. PubMed ID: 22626445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
    Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
    Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Characterization of GSDMB Splicing and Backsplicing Profiles Identifies Novel Isoforms and a Circular RNA That Are Dysregulated in Multiple Sclerosis.
    Cardamone G; Paraboschi EM; Rimoldi V; Duga S; Soldà G; Asselta R
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Not only cancer: the long non-coding RNA MALAT1 affects the repertoire of alternatively spliced transcripts and circular RNAs in multiple sclerosis.
    Cardamone G; Paraboschi EM; Soldà G; Cantoni C; Supino D; Piccio L; Duga S; Asselta R
    Hum Mol Genet; 2019 May; 28(9):1414-1428. PubMed ID: 30566690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.